Home > Press > NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles
Nanovalent Pharmaceuticals of Bozeman, Montana has entered into a collaboration with oncology researchers at Children's Hospital of Los Angeles. The partnership will focus on generating efficacy data in murine models of Ewing's Sarcoma and Acute Lymphoblastic Leukemia utilizing Nanovalent's drug candidates NANO-EW and NANO-ALL.
NanoValent Pharmaceutical Partners with Children's Hospital of Los Angeles
Bozeman, MT | Posted on December 1st, 2007
NANO-EW, NanoValent's lead cancer drug candidate is a transferrin surface targeted nanoparticle loaded with the chemotherapeutic SN38. The Company's primary indication is Ewing's Sarcoma. However, the firm intends to expand development efforts to include non-small cell lung cancer and hepatocellular carcinoma.
NANO-ALL is a transferrin surface targeted nanoparticle delivering siRNA fragments intended to silence gene sequences specific to acute lymphoblastic leukemia.
The Company is developing therapeutics against pediatric and adult cancers using proprietary polymerized liposomal nanoparticle (PLN) drug delivery technology.
About Nanovalent Pharmaceuticals
NanoValent Pharmaceuticals, Inc. (NVP) is a Delaware C-corporation commercializing a drug delivery platform that differentiates itself from other particle delivery systems through several key features. NanoValent particles are highly robust, customizable, stable, cheap, and easy to manufacture. The technology is capable of delivering a wide array of drug molecules or drug cocktails using multiple tissue targeting ligands. While other firms have successfully used targeted particles to deliver pharmaceuticals, few competitors have a payload specific custom offering with the flexibility to target using any surface ligand and deliver virtually any drug or biological payload. The platform product and manufacturing protocols are complete and the company has secured patents along with significant grant funding. The Company’s strategy is to develop several internal delivery programs, while leveraging the versatility of the platform technology providing custom drug delivery solutions to academic and private drug development programs. Internal development efforts are focused on vaccines, cancer therapeutics, and RNAi delivery.
James Hamilton MD, MBA
Jon Nagy PhD
Tim Trich MD, PhD
Chief Medical Officer
Copyright © NanoValent Pharmaceuticals, Inc.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014
QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
IRLYNX and CEA-Leti to Streamline New CMOS-based Infrared Sensing Modules Dedicated to Human-activities Characterization October 15th, 2014
New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014
VDMA photonics steering committee with new members stronger than ever October 14th, 2014